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Abstract
BACKGROUND: The value of PET/CT imaging in diagnosis 
of different cancers has been widely described. PET/CT may 
contribute to visualization of additional findings that were not 
the indication to the study and did not refer to initial diagnosis. 
In a small number of PET/CT scans an incidentally found focal 
18F-FDG uptake in the thyroid gland is found. 
The goal of the study was to estimate the prevalence 
and evaluate the clinical significance of incidental thyroid 
18F-FDG uptake in a cohort of patients diagnosed for different 
malignancies.
MATERIAL AND METHODS: 2478 PET/CT scans using 18F-FDG 
were performed in 1925 subjects for evaluation of different, 
non-thyroid malignancies. For PET/CT examination, a Discovery 
ST (General Electric) PET/CT scanner was used. Patients with 
focal 18F-FDG activity were further evaluated by means of fine 
needle aspiration biopsy (FNAB). If cytological examination 
disclosed malignancy or suspicion of malignancy, thyroidectomy 
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was performed. Both cytological and histopathological results 
were then analyzed.
RESULTS: Focal increased 18F-FDG uptake was found in 71 
patients (3.7%), and cytological or histopathological results were 
evaluable in 20 of them. In general, 8 cases of thyroid cancer 
were found, which accounts for 40% probability of malignancy. 
The predominant histopathological diagnosis was papillary 
thyroid carcinoma (5 out of 8 cases). Additionally, in one case 
(5%) thyroid metastasis of lung cancer was detected.
Diffused 18F-FDG activity in both thyroid lobes was observed 
in 120 subjects (6.2%) — in most cases chronic thyroiditis was 
confirmed.
CONCLUSIONS: The probability of malignancy of focal thyroid 
incidentalomas in 18F-FDG PET/CT scans is rather high. There-
fore, thorough evaluation of such lesions is highly recommended 
in each case. Most thyroid malignancies incidentally detected 
in PET/CT are papillary carcinomas.
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thyroid carcinoma
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Introduction
In the last decade, positron emission tomography (PET) ima-
ging became one of the most beneficial and accurate diagnostic 
tools in oncological diagnosis. Especially when combined with 
computed tomography (PET/CT), its accuracy in imaging ma-
lignant tissue increases up to 93% compared to PET scan only 
(78–85%) [1, 2]. There are many reports confirming its utility in 
patients with lymphoma, lung cancer, breast cancer, colorectal 
cancer and liver metastases, oesophageal cancer, head and 
neck tumours, and melanoma as well as tumours of unknown 
origin [3–10]. The role of PET in thyroid cancer management 
has been widely described. It should be routinely performed in 
patients previously treated for well-differentiated (follicular or 
papillary) thyroid cancer when the whole-body scan performed 
with radioiodine is negative and the thyroglobulin is markedly 
elevated [11]. 
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Apart from this situation, PET/CT may contribute to visualization 
of additional findings that were not the indication to the study and 
did not refer to initial diagnosis. About 1-2% of such incidental find-
ings localize in the thyroid gland [12–15]. Significantly increased 
18F-fluorodeoxyglucose (18FDG) uptake in these patients still 
seems not to be clarified. As sufficient data is missing, fine needle 
aspiration biopsy still remains conclusive in the final diagnosis. 
Aim of the study
The purpose of the study was to assess the prevalence and 
evaluate the clinical significance of incidental thyroid 18F-FDG 
uptake in a cohort of patients diagnosed for other malignancies.
Material and methods
PET/CT scans using 18F-FDG performed between May 2008 
and January 2010 for non-thyroid malignancies were retrospec-
tively analysed. Oncological diagnoses were: non-small cell lung 
cancer, colorectal cancer, non-Hodgkin or Hodgkin lymphoma, 
breast cancer, head and neck cancer, and cancer of unknown 
origin. The main indications for PET/CT comprised: staging 
of the disease, detection of recurrence in patients treated 
previously with surgery, chemotherapy and radiotherapy, and 
detection of the primary focus in subjects with metastases of 
unknown origin.
For PET/CT examination, a Discovery ST (General Elec-
tric) PET/CT scanner was used. All subjects fasted for at least 
6 hours. Diabetic patients with blood glucose level > 160 mg/dl 
were rescheduled. Image acquisition for the whole body scan 
started 60 ± 10 min after intravenous administration of 550 MBq 
of 18F-FDG. Whole body emission scans included 7–8 bed posi-
tions for 3 min in each position. In this study, a focal thyroid lesion 
was defined as a focally increased 18F-FDG uptake on the PET 
images while diffuse thyroid lesion was defined as 18F-FDG uptake 
in the whole thyroid gland. 
Patients with focal 18F-FDG activity were further evaluated by 
means of fine needle aspiration biopsy (FNAB). Ultrasound-guided 
FNAB was performed by an experienced endocrinologist using 
needles with diameter Ø 0.42 mm. The specimens were analyzed 
by an experienced cytologist. Patients in whom FNAB was positive 
or suspected for thyroid malignancy were subjected to thyroid-
ectomy. Both cytological and histopathological results were then 
analyzed.
Results
A total of 2478 PET scans with the use of 18F-FDG in 1925 sub-
jects were performed in the study period. 1003 men and 922 
women aged 1–85 years (mean 54.4 ± 29.6 yrs) were evaluated. 
Focal increased 18F-FDG uptake was found in 71 patients (3.7%) 
(Figure 1). Thyroid FNAB cytological results were available in 20 
out of 71 subjects. 
The cytological diagnoses in this group were as follows: 
7 colloid nodules (benign lesions), 2 oxyphilic nodules (1 ma-
lignancy — papillary thyroid cancer in post-surgery evaluation), 
5 papillary cancers, and one case of metastatic lesion with 
primary origin in lungs. In one case, immunohistochemical stain-
ing of FNAB specimen diagnosed medullary thyroid carcinoma 
(Figures 1 and 2). 
In 2 cases FNAB was inconclusive and repetition of the pro-
cedure was recommended (results unavailable). In 2 cases fol-
licular tumours were diagnosed in FNAB. One of them appeared 
to be follicular adenoma in post-surgical evaluation, in the 
second case the surgery was not performed due to medical 
contraindications. 
Figure 1. Incidentally found focus of increased 18F-FDG uptake in a patient diagnosed due to a pulmonary nodule that appeared benign in the 
PET/CT scan (MIP image and fused axial image are presented). FNAB diagnosed benign thyroid nodule. 
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In general, after both cytological and histological examinations, 
8 malignancies were found, which accounts for 40% of malignan-
cies out of all 20 examined 18F-FDG-avid focal lesions (Figure 3).
Diffused 18F-FDG activity in both thyroid lobes was ob-
served in 120 subjects (6.2%). Patients presenting diffused 
18F-FDG uptake in the thyroid were suspected of autoimmune 
thyroid disease that was then confirmed in laboratory find-
ings (elevated serum thyroid antibodies) and characteristic 
hormonal and clinical status. These patients were not evaluated 
in the current study.
Figure 3. Distribution of FNAB and histopathological diagnoses in the study group.
Figure 2. In a patient with colorectal cancer PET/CT did not detect any cancer recurrence. Incidentally found metabolically active thyroid nodule 
was diagnosed as a medullary thyroid carcinoma (MIP image and fused axial image are presented).
1925 patients diagnosed 
with PET/CT
71 patients (3.7%) 
with focal uptake in PET
120 patients (6.2%) 
with diffused uptake in PET
FNAB available in 20 subjects
7 colloid 
nodules
2 oxyphilic 
tumours
5 papilllary 
cancers
1 metastatic 
lesion
4 inconclusive 
FNAB results
1 medullary 
thyroid carcinoma
1 papilllary 
cancer
1 oxyphilic 
adenoma
2 non-diagnostic 
FNAB results 
(unknown past 
FNAB history)
2 follicular 
tumours
1 follicular 
adenoma
1 follicular 
cancer
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Discussion
Our study seems to confirm previous studies conducted 
in other centres. The prevalence of incidental focally increased 
18F-FDG metabolism ranges, depending on study cohort, from 
1.0% to 4.3% [16, 17]. In the biggest retrospective study devel-
oped thus far, Shie et al. estimated the occurrence of thyroid 
incidentaloma in more than 55,000 subjects evaluated with PET 
for 1%, whereas 33.2% of focal thyroid lesions  were found to be 
malignant. Moreover, Chen et al. revealed incidental focal 18F-FDG 
thyroid uptake in 1.2% of a healthy population proving no link with 
the initial malignancy [15]. 
Obviously, the crucial problem of the thyroid incidentalo-
mas is the differential diagnosis between benign and malignant 
lesions. There have been several studies trying to clarify why only 
some benign lesions present increased 18F-FDG uptake, while the 
majority of papillary cancers are 
18F-FDG-avid. The potential role 
of maximal standardized uptake value (SUVmax) seems to be the 
most commonly investigated aspect. Conclusions of published 
studies are inconsistent. Zhai et al. demonstrated significantly 
higher SUVmax values in malignant than in benign lesions, estimat-
ing SUVmax above 8 as a strong predictor of malignancy. In other 
studies, the highest SUVmax of malignant thyroid lesions was also 
significantly higher than that of benign lesions [23]. A significant 
correlation between SUVmax and maximal diameter of the thyroid 
incidentaloma was also found [24]. However, it has also been 
demonstrated that low SUVmax in a thyroid focus does not exclude 
malignancy. Other authors concluded no significant difference in 
SUVmax between benign and malignant nodules [19, 25]. In ano-
ther study, Kim et al. tried to evaluate the utility of 18F-FDG PET in 
predicting malignancy in thyroid nodules cytologically diagnosed 
as follicular neoplasm. Unfortunately, in this case glucose meta-
bolic activities of benign follicular nodules were as high as those 
of malignant nodules [13]. These conflicting data suggest that 
SUVmax alone is not an adequate tool in differential diagnosis of 
malignant and benign thyroid nodules. Kwak et al. showed the 
added value of sonography in the evaluation of 18F-FDG-positive 
thyroid lesions. The probability (13.2%) of malignancy in such 
cases was much lower when the sonographic findings appeared 
benign, as compared with patients with nodules sonographically 
suspected of malignancy (75.5%) [26]. Unfortunately, the malig-
nant sonographic appearance is still operator-dependant, even if 
these suspicious features are defined by some ultrasound guide-
lines. As shown above, the problem of incidentally found thyroid 
nodules has not been adequately solved and needs further evalu-
ation. Our centre continues to collect a database of such lesions in 
order to obtain data sufficient for more profound evaluation.
Eight out of 20 patients (40%) with 18 FDG-avid lesions were 
eventually diagnosed with thyroid cancer. In 6 of 20 subjects pap-
illary carcinoma was diagnosed. According to previous reports, 
most of the malignancies in focal 18F-FDG-avid lesions are well-dif-
ferentiated papillary carcinomas. Are et al. found this diagnosis in 
19 out of 20 examined patients [27]. In our opinion, in spite of all 
those facts, FNAB should remain the crucial diagnostic tool in the 
evaluation of focal thyroid lesions. 
Sebastianes et al. reported a high negative predictive value of 
PET in detecting malignancies in preoperative evaluation of sus-
pected nodules if the preoperative FNAB result was inconclusive. 
All 18FDG-avid nodules were confirmed to be cancers (100%), 
while almost 39% of benign lesions appeared to present increased 
18F-FDG uptake. In our study only one out of 4 patients with 
previous inconclusive FNAB result was diagnosed with follicular 
adenoma in histopathological examination. Currently, data is be-
ing collected to analyze whether PET/CT is helpful in decreasing 
the amount of unnecessary thyroidectomies due to inconclusive 
cytological findings.
Distant metastases that locate in the thyroid gland are rather 
rare. Occasionally, some of the malignant lesions found in thyroid 
with the means of PET/CT appear to be metastatic [30]. These data 
are confirmed in our study population of oncological patients: only 
one focus of an extrathyroid origin was detected — it was a me-
tastasis of non-small cell lung carcinoma.
In 6.2% of our patients diffused thyroid uptake of 18F-FDG 
was found. The most likely diagnosis is chronic thyroiditis. In 
fact, many of these patients had already been treated with L-
thyroxin before performing the scan. Although diffused 18F-FDG 
uptake seems to be quite accurate in confirming the diagnosis of 
Hashimoto thyroiditis [19, 21], a risk of thyroid cancer in both 
diffuse and combined 18F-FDG uptake should be kept in mind 
[18, 22]. Additionally, the presence of Hashimoto disease with 
a large goitre may impair the diagnostic value of 18FDG PET 
in primary thyroid lymphoma [20]. Therefore, thyroid FNAB 
seems to be obligatory in cases of coexisting diffused 18F-FDG 
uptake in PET scans and the occurrence of lesions seen in thy-
roid sonography. In our study FNAB results were available only 
in a few cases of diffused 18FDG uptake; all of them reported 
Hashimoto thyroiditis.
Conclusions
The probability of malignancy in the case of focal 18F-FDG ac-
cumulation in the thyroid gland is rather high. Therefore, thorough 
evaluation of such lesions is highly recommended in each case. 
Most thyroid malignancies incidentally detected in PET/CT are 
papillary carcinomas. 
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